title: Fibrous dysplasia. Clinical review and therapeutic management.
abstract: Fibrous dysplasia is a skeletal disorder that is associated with a wide spectrum of clinical manifestations, including localized asymptomatic forms and extensive severe forms with severe bone deformities and endocrinological alterations, depending on age, location, extent and associated processes. Although the treatment of choice is based on bisphosphonates, the therapeutic efficacy of these agents in the control of disease activity remains uncertain. This article reviews the current data available on the treatment of this disease as well as the preliminary data on new therapeutic approaches.
authors.affiliation: Servicio de Reumatología, Hospital Clínic, Universidad de Barcelona, Barcelona, España.
authors.forename: Helena
authors.initials: H
authors.lastname: Florez
authors.affiliation: Servicio de Reumatología, Hospital Clínic, Universidad de Barcelona, Barcelona, España. Electronic address: pperis@clinic.ub.es.
authors.forename: Pilar
authors.initials: P
authors.lastname: Peris
authors.affiliation: Servicio de Reumatología, Hospital Clínic, Universidad de Barcelona, Barcelona, España.
authors.forename: Núria
authors.initials: N
authors.lastname: Guañabens
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use; D000089703:Fibroblast Growth Factor-23; D005357:Fibrous Dysplasia of Bone / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; C000717427:FGF23 protein, human; D000089703:Fibroblast Growth Factor-23
keywords: Bisfosfonatos; Bisphosphonates; Denosumab; Displasia fibrosa; FGF-23; Fibrous dysplasia; McCune-Albright syndrome; Síndrome de McCune-Albright